Evidence map›Paper›PMID 27462193›Full record

ArticleCase reports in gastroenterology

Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation.

Reina Sasaki, Tatsuo Kanda, Shin Yasui, Yuki Haga, Masato Nakamura, Mutsumi Yamato, Shuang Wu, Shingo Nakamoto, Makoto Arai, Shigeru Mikami and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Reina SasakiDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Tatsuo KandaDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Shin YasuiDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Yuki HagaDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Masato NakamuraDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Mutsumi YamatoDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Shuang WuDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Shingo NakamotoDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan; Department of Molecular Virology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Makoto AraiDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Shigeru MikamiDepartment of Internal Medicine, Kikkoman General Hospital, Noda, Japan.
Hideaki MiyauchiDepartment of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba, Japan.
Hisahiro MatsubaraDepartment of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba, Japan.
Osamu YokosukaDepartment of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba, Japan.
Chiba University · JPKikkoman (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection leads to acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Following kidney transplantation, HCV increases the risk of graft loss and patient mortality compared with uninfected patients. The achievement of a sustained virological response with antiviral therapy improves survival and diminishes the risk of hepatic decompensation in HCV patients after a kidney transplant. It has been reported that direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of HCV in patients who are liver transplant recipients. In the present study, we investigated HCV eradication via interferon-free therapies with DAAs in two HCV patients with advanced liver fibrosis following renal transplantation. In both cases, the interferon-free regimens with DAAs were effective in eradicating HCV in the patients after kidney transplantation. No adverse events caused by interferon were identified with the exception of anemia. Interferon-free regimens with DAAs for recurrent HCV in patients following kidney transplantation are relatively safe and effective. However, attention should be focused on anemia during these treatments.

Indexed as

Direct-acting antiviralsHepatitis C virusKidney transplantationSustained virological response

Identifiers

PMID27462193
PMCPMC4939684
OpenAlexW2402379619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.